• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LEUCOVORIN Drug Record

  • Summary
  • Interactions
  • Claims
  • LEUCOVORIN chembl:CHEMBL1679 ApprovedAntineoplastic

    Alternate Names:

    LEUCOVORIN

    Drug Info:

    Drug Class vitamins/minerals
    Year of Approval approved before 1982
    Drug Class antineoplastic adjuncts
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications adjuvant to chemotherapy
    (4 More Sources)

    Publications:

    Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
    Chen et al., 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system., Cancer Res.
    Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud
    Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
    Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
    Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
    Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
    Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
    van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
    Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
    Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
    Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
    Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
    Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
    Hou Z et al., 2005, Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods., J Biol Chem
    Wang L et al., 2011, Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase., J Med Chem
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Ogino et al., 2007, CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma., Virchows Arch.
    Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Ichikawa et al., 2003, Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer., Clin. Cancer Res.
    Ishida et al., 2002, [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]., Gan To Kagaku Ryoho
    Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
    Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
    De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
    McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
    Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
    Etienne-Grimaldi MC et al., 2010, Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients., Br J Clin Pharmacol
    Huang MY et al., 2008, ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study., BMC Cancer
    Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
    Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
    Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
    Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Chen S et al., 2015, ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients., Pharmacogenet Genomics
    Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
    Tsunoda A et al., 2011, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study., Ann Oncol
    Ichikawa W et al., 2006, Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen., Clin Cancer Res
    Etienne-Grimaldi MC et al., 2012, Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan., Br J Clin Pharmacol
    Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.
  • LEUCOVORIN   RUNX3

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17372756


    Sources:
    NCI

  • LEUCOVORIN   DPYD

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12576451 11977552 31871216


    Sources:
    NCI CIViC PharmGKB

  • LEUCOVORIN   XRCC3

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549067


    Sources:
    PharmGKB

  • LEUCOVORIN   ABCG1

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26352872


    Sources:
    PharmGKB

  • LEUCOVORIN   KLC1

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549067


    Sources:
    PharmGKB

  • LEUCOVORIN   UMPS

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20647221 16818689


    Sources:
    PharmGKB

  • LEUCOVORIN   RGS5

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25069475


    Sources:
    PharmGKB

  • LEUCOVORIN   MTHFR

    Interaction Score: 1.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593


    Sources:
    PharmGKB

  • LEUCOVORIN   ERCC2

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20385995 20078613 18267032


    Sources:
    PharmGKB

  • LEUCOVORIN   SHMT1

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22044939


    Sources:
    PharmGKB

  • LEUCOVORIN   SLC19A1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16115875 21879757


    Sources:
    DTC PharmGKB

  • LEUCOVORIN   ABCC5

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26352872


    Sources:
    PharmGKB

  • LEUCOVORIN   SELE

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24980946


    Sources:
    PharmGKB

  • LEUCOVORIN   ERCC1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23314736 21057378


    Sources:
    PharmGKB

  • LEUCOVORIN   GATA3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • LEUCOVORIN   APC

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Clinical Study
    Response Type no benefit

    PMIDs:
    27626067


    Sources:
    JAX-CKB

  • LEUCOVORIN   VEGFA

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25955730 20125120


    Sources:
    PharmGKB

  • LEUCOVORIN   ABCC4

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12036927


    Sources:
    NCI

  • LEUCOVORIN   ABCG2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 24018773 20530282


    Sources:
    PharmGKB

  • LEUCOVORIN   TYMS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Fusilev
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • LEUCOVORIN   BAX

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11237386


    Sources:
    NCI

  • LEUCOVORIN   ABCC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23314736


    Sources:
    PharmGKB

  • LEUCOVORIN   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    27626067 28784859 26432108


    Sources:
    JAX-CKB

  • LEUCOVORIN   GSTP1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LEUCOVORIN   BRAF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Fluorouracil + Leucovorin + Trastuzumab
    Indication/Tumor Type rectum adenocarcinoma
    Response Type no benefit

    PMIDs:
    27626067


    Sources:
    JAX-CKB

  • LEUCOVORIN   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • LEUCOVORIN   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20921465


    Sources:
    CIViC

  • LEUCOVORIN   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22486600


    Sources:
    PharmGKB

  • TEND: LEUCOVORIN

    • Version: 01-August-2011

    Alternate Names:
    LEUCOVORIN Primary Drug Name

    Drug Info:
    Drug Class antineoplastic adjuncts
    Year of Approval approved before 1982
    Drug Class vitamins/minerals

    Publications:

  • TdgClinicalTrial: LEUCOVORIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications adjuvant to chemotherapy
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: LEUCOVORIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1679 ChEMBL Drug ID

    Drug Info:

    Publications:
    Wang L et al., 2011, Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase., J Med Chem

  • NCI: LEUCOVORIN

    • Version: 14-September-2017

    Alternate Names:
    C607 NCI drug code

    Drug Info:

    Publications:
    Ogino et al., 2007, CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma., Virchows Arch.
    Ishida et al., 2002, [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]., Gan To Kagaku Ryoho
    Ichikawa et al., 2003, Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer., Clin. Cancer Res.

  • PharmGKB: leucovorin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
    Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
    Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One

  • JAX-CKB: Leucovorin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw

  • CIViC: LEUCOVORIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
    Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.

  • ChemblDrugs: chembl:CHEMBL1679

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21